Denali Therapeutics
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics: Series C Funding Round
Denali Therapeutics has successfully raised $217M in Series C funding, reaching a valuation of $5B.
Company Overview
Neurodegeneration therapeutics
Funding Details
The Series C round was led by Baillie Gifford, with participation from Redmile Group, Vivo Capital, GV, Fidelity.
Company Information
- Headquarters: 161 Oyster Point Boulevard, South San Francisco, CA 94080
- Founded: 2015
- Employees: 600+
- Category: Biotech
Investment
Denali Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Baillie Gifford: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Vivo Capital: Verified investor in Series C
- GV: Verified investor in Series C
- Fidelity: Verified investor in Series C
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free